Skip to main content

Predictors of treatment (tx) duration in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) treated with enzalutamide (ENZA): A post hoc analysis of ARCHES.

Conferences
Armstrong, AJ; Petrylak, DP; Shore, ND; Szmulewitz, RZ; Holzbeierlein, JM; Villers, A; Alcaraz, A; Alekseev, B; Iguchi, T; Gomez-Veiga, F ...
Published in: Journal of Clinical Oncology
June 1, 2026

In ARCHES (NCT02677896), ENZA + androgen-deprivation therapy (ADT) significantly improved radiographic progression-free survival (primary: data cutoff, Oct 14, 2018) and overall survival (prespecified secondary: data cutoff, May 28, 2021; 5-year follow-up: data cutoff, Jul 31, 2024) vs placebo + ADT in mHSPC. This post hoc analysis explored factors associated with different ENZA tx durations (5-year follow-up). Reasons for tx discontinuation (DC) including toxicity and progression, and baseline and on-treatment factors underlying tx persistence, were compared descriptively among pts with short (0–2 years [y]; STx), medium (2–5 y; MTx), and long Tx duration (> 5 y; LTx) (STx pts represent non-responders; MTx/LTx pts represent tx responders). Of 572 ENZA-treated pts, 204 (36%) were STx; 140 (24%) MTx; 228 (40%) LTx. STx pts were more likely to be older vs MTx and LTx, with high-volume disease (HVD) and Eastern Cooperative Oncology Group performance status (ECOG PS) 1, although 55.3% of LTx had HVD and 73.2% had synchronous metastases. Progressive disease and tx-emergent adverse events (TEAEs) were the most common reasons for tx DC. Drug-related TEAEs (per 100 pt-y) were more common in STx (156.0) vs MTx (89.5) and LTx (47.1), as were those leading to tx DC (STx: 12.4; MTx: 1.5; LTx: 0.1). Rates (per 100 pt-y) of TEAEs leading to ENZA dose reduction were higher in STx (6.2) vs MTx (5.8) and LTx (2.0). The rate (per 100 pt-y) of drug-related TEAEs of special interest were generally higher in STx vs MTx and LTx: convulsions (1.0 vs 0.0 vs 0.0); fatigue (19.0 vs 10.7 vs 4.8), select cardiovascular events (1.0 vs 0.6 vs 0.1); falls (2.4 vs 3.2 vs 1.1); fractures (0.5 vs 1.5 vs 0.5). Our findings demonstrate that LTx and MTx tended to have more favorable pt and disease characteristics vs STx, although majority of LTx had adverse prognostic features. While progressive disease was the most common reason for DC, AEs/withdrawals were the second most common. Most TEAEs of special interest were more frequent in STx. Reasons for AE-related tx changes are multifactorial, and optimal management of AEs and comorbidities, as well as dose modifications, can optimize ENZA tx. .

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

June 1, 2026

Volume

44

Issue

16_suppl

Start / End Page

5093 / 5093

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Armstrong, A. J., Petrylak, D. P., Shore, N. D., Szmulewitz, R. Z., Holzbeierlein, J. M., Villers, A., … Azad, A. (2026). Predictors of treatment (tx) duration in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) treated with enzalutamide (ENZA): A post hoc analysis of ARCHES. In Journal of Clinical Oncology (Vol. 44, pp. 5093–5093). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2026.44.16_suppl.5093
Armstrong, Andrew J., Daniel P. Petrylak, Neal D. Shore, Russell Zelig Szmulewitz, Jeffrey M. Holzbeierlein, Arnauld Villers, Antonio Alcaraz, et al. “Predictors of treatment (tx) duration in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) treated with enzalutamide (ENZA): A post hoc analysis of ARCHES.” In Journal of Clinical Oncology, 44:5093–5093. American Society of Clinical Oncology (ASCO), 2026. https://doi.org/10.1200/jco.2026.44.16_suppl.5093.
Armstrong AJ, Petrylak DP, Shore ND, Szmulewitz RZ, Holzbeierlein JM, Villers A, et al. Predictors of treatment (tx) duration in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) treated with enzalutamide (ENZA): A post hoc analysis of ARCHES. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2026. p. 5093–5093.
Armstrong, Andrew J., et al. “Predictors of treatment (tx) duration in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) treated with enzalutamide (ENZA): A post hoc analysis of ARCHES.” Journal of Clinical Oncology, vol. 44, no. 16_suppl, American Society of Clinical Oncology (ASCO), 2026, pp. 5093–5093. Crossref, doi:10.1200/jco.2026.44.16_suppl.5093.
Armstrong AJ, Petrylak DP, Shore ND, Szmulewitz RZ, Holzbeierlein JM, Villers A, Alcaraz A, Alekseev B, Iguchi T, Gomez-Veiga F, Serikoff A, Croitoru R, Rosales M, Kalac M, Tang Y, Stenzl A, Azad A. Predictors of treatment (tx) duration in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) treated with enzalutamide (ENZA): A post hoc analysis of ARCHES. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2026. p. 5093–5093.

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

June 1, 2026

Volume

44

Issue

16_suppl

Start / End Page

5093 / 5093

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis